Smoking Rates Hit Historic Low in US amid Pandemic

Mar.23.2022
Smoking Rates Hit Historic Low in US amid Pandemic
Smoking rates hit an all-time low in the US during the first year of the pandemic, attributed to public health campaigns and lifestyle changes.

According to foreign media reports on March 17, 2022, New York - in the first year of the COVID-19 pandemic, an increasing number of Americans have been abusing alcohol or using illegal drugs, but apparently not smoking.

 

According to survey data released on Thursday by the U.S. Centers for Disease Control and Prevention, smoking rates in the United States have reached a historic low in 2020, with only 1 in 8 adults reporting current use. The CDC also reported a decrease in adult e-cigarette usage.

 

Officials from the Disease Prevention and Control Center attributed this decline to public health campaigns and policies. However, outside experts suggest that increased prices for tobacco products and changes in lifestyle due to epidemics may have also played a role.

 

People who are mainly social smokers no longer have this situation," said Megan Roberts, a researcher at Ohio State University who focuses on tobacco product use among young people and adolescents.

 

More importantly, parents who suddenly had to stay home full-time with their children may have already cut back on expenses. Roberts also added that some individuals may have quit smoking after reports came out suggesting that smokers are more likely to develop severe illnesses if infected with COVID-19.

 

According to a report from the Centers for Disease Control and Prevention, based on a survey of over 31,000 American adults, 19% of Americans used at least one tobacco product in 2020, which is lower than the approximately 21% reported in 2019.

 

The use of cigars, smokeless tobacco, and pipes remain unchanged. Currently, the usage rate of electronic cigarettes has decreased from 4.5% in the previous year to 3.7%.

 

Cigarettes are the most commonly used tobacco product, with 12.5% of adults using them, which is lower than the 14% average.

 

For a long time, public health officials have believed that smoking - a risk factor for lung cancer, heart disease and stroke - is the leading cause of preventable deaths in the United States.

 

In 1965, 42% of American adults were smokers.

 

For several decades, this ratio has been gradually declining for various reasons, including taxes and smoking bans in workplaces and restaurants. However, some experts argue that a significant portion of the recent decline is due to the recent increase in prices.

 

For example, British American Tobacco - a company that produces brands such as Camel, Lucky Strike, and Newport - increased their prices fourfold in 2020, resulting in a total increase of around 50 cents per pack.

 

Interestingly, the amount of cigarettes sold in the United States actually increased in 2020, according to a report from the Federal Trade Commission. This is the first such growth in twenty years.

 

While there may be fewer smokers, those who do smoke tend to smoke more heavily.

 

This is a viable hypothesis - that people have more opportunities to smoke because they are not working," said David Sweanor, the global tobacco policy expert at the University of Ottawa.

 

He said that the investigation by the Disease Prevention and Control Center may also underestimate the number of smokers, either because some interviewees are dishonest or because the investigation missed too many smokers.

 

Other surveys have indicated that alcohol and illegal drug use have increased for many people during the first year of the pandemic.

 

(Source: Associated Press)

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Japan Tobacco (JT) will expand EVO Cacao Mint Crystal from limited channels to nationwide retail in Japan from October 6, 2026. The Ploom tobacco stick ranked first in the brand's first consumer voting campaign for new tobacco-stick SKUs held earlier this year. JT will also introduce a limited 22-stick pack at the same JPY 620 price as the standard 20-stick pack. The capsule-format product combines menthol with sweet, bittersweet cacao notes and adds a berry nuance when the capsule is crushed.
Sep.09
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Kantar Study Finds More Than 93% of Vape Products in Ukraine Fail Regulatory Requirements
Kantar Study Finds More Than 93% of Vape Products in Ukraine Fail Regulatory Requirements
According to Interfax-Ukraine, a study conducted by market research firm Kantar Ukraine at the request of major tobacco companies found that more than 93% of vape products in Ukraine did not fully comply with regulatory requirements. The research examined product categories, brand distribution and consumer purchasing channels, showing that pod systems and disposable vapes represent major segments of the market, while offline retail remains the dominant purchasing channel. The findings highlight ongoing compliance challenges in Ukraine’s vape market.
Aug.26